<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04829331</url>
  </required_header>
  <id_info>
    <org_study_id>21-RES-003</org_study_id>
    <nct_id>NCT04829331</nct_id>
  </id_info>
  <brief_title>Utility of Restrata With Split Thickness Skin Graft to Reconstruct the Forearm Donor Site</brief_title>
  <official_title>Utility of Restrata With Split Thickness Skin Graft to Reconstruct the Forearm Donor Site</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acera Surgical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acera Surgical, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Understand association between use of Restrata (Acera Surgical Inc., St. Louis, MO) in&#xD;
      forearm flap reconstruction with donor site healing and function&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 9, 2021</start_date>
  <completion_date type="Anticipated">July 23, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 9, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tendon exposure</measure>
    <time_frame>4 weeks post-operatively</time_frame>
    <description>Percentage of participants with tendon exposure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Surface area of split-thickness skin graft incorporation</measure>
    <time_frame>4 weeks post-operatively</time_frame>
    <description>Percentage of surface area of split-thickness skin graft incorporation</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Wound Heal</condition>
  <arm_group>
    <arm_group_label>Restrata with a split-thickness skin graft</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Split-thickness skin graft alone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Restrata</intervention_name>
    <description>Restrata is a sterile, single use device intended for use in local management of wounds</description>
    <arm_group_label>Restrata with a split-thickness skin graft</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. All patients age 19 or greater that will undergo radial forearm free flap or ulnar&#xD;
             free flap.&#xD;
&#xD;
          2. Photo documentation of wound bed at two weeks and four weeks must be obtainable either&#xD;
             by physician or patient.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active systemic immunosuppression (active use of high-dose steroids (≥40mg prednisone&#xD;
             daily or equivalent) or other immunosuppressive medications OR medical conditions&#xD;
             causing immunosuppression, i.e. human immunodeficiency virus etc).&#xD;
&#xD;
          2. Diabetes mellitus with most recent Hemoglobin A1c ≥10.0 within 30 days prior to&#xD;
             surgery.&#xD;
&#xD;
          3. Morbid obesity (BMI &gt;40).&#xD;
&#xD;
          4. Inability to maintain wrist immobilization for full planned period.&#xD;
&#xD;
          5. Severe malnutrition (prealbumin levels &lt;10 mg per dL within 30 days prior to surgery&#xD;
             OR BMI &lt;15 (very severely underweight).&#xD;
&#xD;
          6. Other conditions felt to significantly impair wound healing per surgeon discretion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nebraska Methodist Hospital</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Lindau, MD</last_name>
      <phone>402-354-5048</phone>
      <email>robert.lindauiii@nmhs.org</email>
    </contact>
    <investigator>
      <last_name>Robert Lindau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 31, 2021</study_first_submitted>
  <study_first_submitted_qc>March 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2021</study_first_posted>
  <last_update_submitted>April 15, 2021</last_update_submitted>
  <last_update_submitted_qc>April 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

